MRI with Gadolinium is Preferred Over CT with Contrast in This Patient
In an elderly patient with eGFR 45 mL/min/1.73 m² (CKD stage 3a), MRI with group II gadolinium-based contrast media (GBCM) is the safer choice compared to CT with iodinated contrast, as the risk of nephrogenic systemic fibrosis (NSF) is exceedingly low while iodinated contrast carries meaningful risk of contrast-induced nephropathy in this population. 1, 2
Risk Profile with Gadolinium at eGFR 45
Your patient falls into the moderate chronic kidney disease category (eGFR 30-59 mL/min/1.73 m²), which represents a fundamentally different risk profile than severe renal impairment:
NSF risk is essentially negligible with group II GBCMs at this level of renal function. The ACR-NKF consensus explicitly states that NSF occurs "almost exclusively" in patients with eGFR <30 mL/min/1.73 m² or acute kidney injury. 1
Standard dosing of group II GBCMs can be administered safely without additional precautions in patients with eGFR ≥30 mL/min/1.73 m². 3, 4
The most recent ASNR 2025 statement goes further, recommending that group II GBCAs no longer be withheld in patients with CKD when medically indicated, and that safety measures like checking renal function can be discontinued if exclusively using group II agents. 5
Group II GBCMs to Use
Select macrocyclic agents (gadobutrol, gadoteridol, gadoterate meglumine) or newer linear agents (gadoxetate disodium, gadobenate dimeglumine) for this patient. 1, 2
Macrocyclic GBCMs are thermodynamically stable and kinetically inert, with the lowest dissociation of free gadolinium. 1
A 2022 study of gadoxetate acid in patients with moderate and severe renal impairment found zero cases of NSF (0/340 patients with severe impairment; 95% CI: 0-0.9%). 6
Absolutely avoid: gadopentetate dimeglumine, gadodiamide, and gadoversetamide—these older linear agents remain contraindicated in any degree of renal impairment. 3, 4
Risk Profile with Iodinated Contrast at eGFR 45
Iodinated contrast poses a tangible risk of contrast-induced acute kidney injury in this patient:
The ACR Appropriateness Criteria emphasizes that in CKD, "the risk-benefit ratio is determined by the level and acuity of kidney disease, specifically weighing the benefits versus risks of any contrast agent." 2
While not absolutely contraindicated at eGFR 45, iodinated contrast requires risk mitigation strategies (hydration, avoidance of other nephrotoxins, close monitoring) that are unnecessary with group II GBCMs. 2
Studies comparing gadolinium to iodinated contrast in patients with renal impairment have shown gadolinium to be "obviously less nephrotoxic than iodinated contrast media" in populations with pre-existing renal impairment. 7
Practical Implementation
Administer standard diagnostic doses of group II GBCM without dose reduction:
Use the full recommended dose (typically 0.1 mmol/kg for gadoteridol). 8
Half or quarter dosing is not recommended and may compromise diagnostic quality. 3, 4
No special precautions are required at this eGFR level:
Prophylactic hemodialysis is not indicated and provides no proven benefit for NSF prevention. 3, 4
Post-procedure monitoring for NSF is reasonable but the risk is exceedingly low (much less than 1%). 3, 4
Common Pitfall to Avoid
Do not apply the same restrictions used for eGFR <30 to this patient with eGFR 45. The outdated position that GBCMs are contraindicated in all stages of CKD has been explicitly rejected by current guidelines and may inappropriately limit access to necessary diagnostic imaging. 3, 4, 5
The elimination half-life of gadoteridol is prolonged in renal impairment (10.65 hours in mild-moderate impairment vs 1.57 hours in normal function), but this pharmacokinetic change does not translate to increased NSF risk at eGFR 45. 8